上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2015年
15期
9-13
,共5页
非小细胞肺癌%化疗%靶向治疗
非小細胞肺癌%化療%靶嚮治療
비소세포폐암%화료%파향치료
non-small cell lung cancer%chemotherapy%targeted therapy
目前，对非小细胞肺癌（non-small cell lung cancer, NSCLC）的治疗已经进入靶向治疗时代。对表皮生长因子受体（epidermal growth factor receptor, EGFR）基因状态明确的 NSCLC 患者，其治疗推荐已有共识：对 EGFR 基因突变患者应优先选用 EGFR 酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKI）治疗。但对 EGFR 基因野生型及经 EGFR TKI 一线治疗失败的患者，化疗仍是首选的治疗方式。本文从循证医学角度，通过回顾相关临床研究数据，分析靶向治疗时代下的 NSCLC 化疗的合理选择与联合治疗。
目前，對非小細胞肺癌（non-small cell lung cancer, NSCLC）的治療已經進入靶嚮治療時代。對錶皮生長因子受體（epidermal growth factor receptor, EGFR）基因狀態明確的 NSCLC 患者，其治療推薦已有共識：對 EGFR 基因突變患者應優先選用 EGFR 酪氨痠激酶抑製劑（tyrosine kinase inhibitors, TKI）治療。但對 EGFR 基因野生型及經 EGFR TKI 一線治療失敗的患者，化療仍是首選的治療方式。本文從循證醫學角度，通過迴顧相關臨床研究數據，分析靶嚮治療時代下的 NSCLC 化療的閤理選擇與聯閤治療。
목전，대비소세포폐암（non-small cell lung cancer, NSCLC）적치료이경진입파향치료시대。대표피생장인자수체（epidermal growth factor receptor, EGFR）기인상태명학적 NSCLC 환자，기치료추천이유공식：대 EGFR 기인돌변환자응우선선용 EGFR 락안산격매억제제（tyrosine kinase inhibitors, TKI）치료。단대 EGFR 기인야생형급경 EGFR TKI 일선치료실패적환자，화료잉시수선적치료방식。본문종순증의학각도，통과회고상관림상연구수거，분석파향치료시대하적 NSCLC 화료적합리선택여연합치료。
At present, the treatment of non-small cell lung cancer (NSCLC) has come into the era of targeted therapy. The treatment recommendations for the advanced NSCLC with clear epidermal growth factor receptor (EGFR) gene status have reached a consensus: patients with EGFR mutation-positive NSCLC can give priority to EGFR tyrosine kinase inhibitors, which can maximize the benefit from the treatment; while the patients with wild-type EGFR gene and failure after the first-line treatment should still regard chemotherapy as first choice. We thoroughly review the related clinical trial from the point of view of evidence-based medicine, and analyze the reasonable selection and combination of chemotherapy under the era of targeted therapy.
